Francine Gervais
Corporate Officer/Principal bei McGill University
Aktive Positionen von Francine Gervais
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| McGill University | Corporate Officer/Principal | - | - |
Karriereverlauf von Francine Gervais
Ehemalige bekannte Positionen von Francine Gervais
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| BELLUS HEALTH | Technik-/Wissenschafts-/F&E-Leiter | - | - |
PainCeptor Pharma Corp.
 PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Corporate Officer/Principal | - | - |
Ausbildung von Francine Gervais
| University of Montréal | Doctorate Degree |
Statistik
International
| Kanada | 5 |
Operativ
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sektoral
| Consumer Services | 3 |
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
PainCeptor Pharma Corp.
PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Health Technology |
BELLUS Health, Inc.
 BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
- Börse
- Insiders
- Francine Gervais
- Erfahrung
